Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Pharm ; 657: 124098, 2024 May 25.
Artigo em Inglês | MEDLINE | ID: mdl-38621614

RESUMO

Glaucoma, the second most common cause of blindness worldwide, requires the development of new and effective treatments. This study introduces a novel controlled-release system utilizing elastin-like recombinamers (ELR) and the Supercritical Antisolvent (SAS) technique with supercritical CO2. Acetazolamide (AZM), a class IV drug with limited solubility and permeability, is successfully encapsulated in an amphiphilic ELR at three different ELR:AZM ratios, yielding up to 62 %. Scanning electron microscopy (SEM) reveals spherical microparticles that disintegrate into monodisperse nanoparticles measuring approximately 42 nm under physiological conditions. The nanoparticles, as observed via Transmission Electron Microscopy (TEM) and Atomic Force Microscopy (AFM), do not exhibit aggregates, a fact confirmed by the zeta potential displaying a value of -33 mV over a period of 30 days. Transcorneal permeation tests demonstrate a 10 % higher permeation level compared to the control solution, which increases to 30 % after 2 h. Ocular irritation tests demonstrate no adverse effects or damage. Intraocular pressure (IOP) tests conducted on hypertensive rabbits indicate greater effectiveness for all three analyzed formulations, suggesting enhanced drug bioavailability during treatment. Consequently, the combination of recombinant biopolymers and high-pressure techniques represents a promising approach for advancing glaucoma therapy, emphasizing its potential clinical significance.


Assuntos
Acetazolamida , Elastina , Glaucoma , Pressão Intraocular , Nanopartículas , Coelhos , Animais , Acetazolamida/administração & dosagem , Acetazolamida/química , Acetazolamida/farmacocinética , Glaucoma/tratamento farmacológico , Elastina/química , Pressão Intraocular/efeitos dos fármacos , Nanopartículas/química , Preparações de Ação Retardada/química , Solventes/química , Solubilidade , Masculino , Inibidores da Anidrase Carbônica/administração & dosagem , Inibidores da Anidrase Carbônica/química , Inibidores da Anidrase Carbônica/farmacocinética , Disponibilidade Biológica , Córnea/metabolismo , Córnea/efeitos dos fármacos , Composição de Medicamentos/métodos , Permeabilidade
2.
Biomater Adv ; 154: 213595, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37639856

RESUMO

New strategies to develop drug-loaded nanocarriers with improved therapeutic efficacy are needed for cancer treatment. Herein we report a novel drug-delivery nanosystem comprising encapsulation of the chemotherapeutic drug docetaxel (DTX) and recombinant fusion of a small peptide inhibitor of Akt kinase within an elastin-like recombinamer (ELR) vehicle. This combined approach is also precisely targeted to colorectal cancer cells by means of a chemically conjugated DNA aptamer specific for the CD44 tumor marker. This 53 nm dual-approach nanosystem was found to selectively affect cell viability (2.5 % survival) and proliferation of colorectal cancer cells in vitro compared to endothelial cells (50 % survival), and to trigger both apoptosis- and necrosis-mediated cell death. Our findings also show that the nanohybrid particles remain stable under physiological conditions, trigger sustained drug release and possess an adequate pharmacokinetic profile after systemic intravenous administration. In vivo assays showed that these dual-approach nanohybrids significantly reduced the number of tumor polyps along the colorectal tract in a murine colorectal cancer model. Furthermore, systemic administration of advanced nanohybrids induced tissue recovery by improving the morphology of gastrointestinal crypts and the tissue architecture. Taken together, these findings indicate that our strategy of an advanced dual-approach nanosystem allows us to achieve successful controlled release of chemotherapeutics in cancer cells and may have a promising potential for colorectal cancer treatment.


Assuntos
Antineoplásicos , Neoplasias Colorretais , Nanopartículas , Camundongos , Animais , Docetaxel/farmacologia , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Proteínas Proto-Oncogênicas c-akt , Células Endoteliais , Portadores de Fármacos , Inibidores da Angiogênese , Neoplasias Colorretais/tratamento farmacológico
3.
Curr Med Chem ; 26(40): 7117-7146, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-29737250

RESUMO

Protein-based polymers are some of the most promising candidates for a new generation of innovative biomaterials as recent advances in genetic-engineering and biotechnological techniques mean that protein-based biomaterials can be designed and constructed with a higher degree of complexity and accuracy. Moreover, their sequences, which are derived from structural protein-based modules, can easily be modified to include bioactive motifs that improve their functions and material-host interactions, thereby satisfying fundamental biological requirements. The accuracy with which these advanced polypeptides can be produced, and their versatility, self-assembly behavior, stimuli-responsiveness and biocompatibility, means that they have attracted increasing attention for use in biomedical applications such as cell culture, tissue engineering, protein purification, surface engineering and controlled drug delivery. The biopolymers discussed in this review are elastin-derived protein-based polymers which are biologically inspired and biomimetic materials. This review will also focus on the design, synthesis and characterization of these genetically encoded polymers and their potential utility for controlled drug and gene delivery, as well as in tissue engineering and regenerative medicine.


Assuntos
Materiais Biocompatíveis/química , Pesquisa Biomédica , Elastina/genética , Engenharia Genética , Animais , Elastina/química , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...